The companies that stand out are those that pair a clear compliance strategy with a sustainable business model, one that makes ongoing care simple for patients while giving investors and regulators confidence in how the business operates
This information helps your provider decide whether to maintain the current dose or begin dose escalation at the next scheduled adjustment
By comparison, 4.9 percent of participants taking retatrutide dropped out of the TRIUMPH-1 trial
Cardiometabolic risk factors, such as C-reactive protein, lipids, and blood pressure, were also reduced with semaglutide treatment compared with placebo [49]
In consideration of the dual roles of GLP-1RAs in hypoglycemic effects and preventing CVD among T2DM patients, we reviewed the cardiovascular effects and molecular mechanisms of GLP-1RAs in CVOTs, animal models and cultured cells, and discuss how these findings transform pharmacotherapies for T2DM, and even expand the indication of this important category of anti-diabetic drugs to CVD patients without diabetes